Aktuelle Urologie

Publisher: Georg Thieme Verlag

Journal description

Current impact factor: 0.28

Impact Factor Rankings

2015 Impact Factor Available summer 2015
2013 / 2014 Impact Factor 0.28
2012 Impact Factor 0.474
2011 Impact Factor 0.267
2010 Impact Factor 0.303
2009 Impact Factor 0.206
2008 Impact Factor 0.168
2007 Impact Factor 0.23
2006 Impact Factor 0.4
2005 Impact Factor 0.32
2004 Impact Factor 0.119
2003 Impact Factor 0.073
2002 Impact Factor 0.09
2001 Impact Factor 0.177
2000 Impact Factor 0.181
1999 Impact Factor 0.24
1998 Impact Factor 0.189
1997 Impact Factor 0.168
1996 Impact Factor 0.194
1995 Impact Factor 0.166
1994 Impact Factor 0.154
1993 Impact Factor 0.2
1992 Impact Factor 0.189

Impact factor over time

Impact factor

Additional details

5-year impact 0.30
Cited half-life 5.40
Immediacy index 0.09
Eigenfactor 0.00
Article influence 0.05
ISSN 1438-8820
OCLC 231865149
Material type Internet resource
Document type Internet Resource, Computer File, Journal / Magazine / Newspaper

Publisher details

Georg Thieme Verlag

  • Pre-print
    • Author cannot archive a pre-print version
  • Post-print
    • Author can archive a post-print version
  • Conditions
    • On author's personal website immediately
    • On Institutional Repository and PubMed Central after 12 months embargo
    • Publisher's version/PDF can be used on author's personal website only
    • Publisher copyright and source must be acknowledged
    • Link to Publisher version (www.thieme-connect.com) must be included if article has been published online
    • 'Georg Thieme Verlag' is an imprint of 'Thieme Publishing'
  • Classification
    ​ blue

Publications in this journal

  • [Show abstract] [Hide abstract]
    ABSTRACT: Marketing in economic systems means to create a brand in a competitive surrounding to serve customers as a target. Thereby, elements of marketing are product policy and pricing as well as distribution. Due to the fact that not only products and services are almost not modifiable at all and that price variation is impossible due to the DRG system but also common distribution channels, such as retail or wholesale, are prohibited, the fist mentioned marketing elements are of special importance. Primary customers are the referring physicians who are well served by medical education or presentations, which belong to the common facilities of a hospital department. Nowadays one can observe an increasing mobility of patients and an increasing willingness to inform themselves about medical topics and the service provider behind them. In conclusion, the maintenance of patients is a growing field for the economic success of a hospital or a hospital department. The marketing elements are ruled by the "Heilmittelwerbegesetz" and must fulfill the standards which are defined by this statute. Patient´s journals, a guided tour around the procedure rooms with technical equipment, an after-sales postcard and the participation in events not only with medical contents, such as fairs, can help to steadily establish an image, for example, as an ambitious and caring service provider. Georg Thieme Verlag KG Stuttgart · New York.
    Aktuelle Urologie 05/2015; 46(3):206-10. DOI:10.1055/s-0035-1555705
  • [Show abstract] [Hide abstract]
    ABSTRACT: Urothelial carcinoma of the bladder (UBC) at stage pT1 is a heterogenous disease. Established criteria for prognosis prediction are not suitable for every patient. Choosing the right therapeutic strategy for the individual patient thus remains a challenge. The aim of the present study was to identify clinical parameters regarding cancer-specific survival (CSS) in patients with pT1 UBC. A retrospective analysis of clinical parameters of all patients with a pT1 UBC between 1989 and 2012 from a single centre was performed. Treatment consisted of transurethral resection, second resection followed by initially bladder sparing treatment. Anamnestic data, histopathological reports and clinical course were assessed with CSS being defined as primary endpoint. Kaplan-Meier analysis, uni- and multivariate analysis were performed using SPSS (Version 22, IBM). 378 patients (78% male, median age 72 years) were included, median follow-up was 35 months. Pathological stage pT1G3 (66 vs. 91%, p<0.001), lack of instillation therapy (66 vs. 83%, p<0.001), presence of a second malignoma (41 vs. 77%, p=0,004), diagnosis after 2000 (75 vs. 76%, p=0,018) and tumour progress (42 vs. 85%, p<0.001) were associated with a worse CSS in univariate and Kaplan-Meier analysis. Multivariate analysis revealed the presence of a second malignoma (HR 2.267; CI 95% 1.143-4.497, p=0.019), pathological stage pT1G3 at initial diagnosis (HR 4.567; CI 95% 2.040-10.22, p<0.001) and tumour progress (HR 3.742; CI 95% 1.544-9.069, p=0.003) as independent negative predictors of CSS. Instillation therapy was a prognostic factor for improved CSS (HR 0.368; CI 95% 0.212-0.638, p<0.001). The present study identified the presence of a second malignoma, pathological stage pT1G3 and tumour progress as negative predictive factors for CSS. Maintenance instillation therapy after reresection was associated with an improved CSS. Georg Thieme Verlag KG Stuttgart · New York.
    Aktuelle Urologie 05/2015; 46(3):221-6. DOI:10.1055/s-0035-1549905
  • [Show abstract] [Hide abstract]
    ABSTRACT: Urothelial bladder cancer is characterised by high recurrence and progression rates despite multimodal treatment. Only slight improvements have been achieved during the last decades. The current histopathological classification and clinical risk stratification tools are inaccurate. Hence, a better understanding of the tumour biology is essential for the improvement of patient care. The molecular characterisation of bladder cancer may be translated into useful diagnostic and predictive biomarkers. Many potential therapeutic targets have been identified such as FGFR3 (Fibroblast growth factor receptor 3), HER2 (human epidermal growth factor receptor 2) and PD1/PDL1 (programmed cell death-1). They need validation in clinical trials. We now review the molecular biology of urothelial bladder carcinoma and discuss clinical applications of biomarkers and targeted therapies. © Georg Thieme Verlag KG Stuttgart · New York.
    Aktuelle Urologie 05/2015; 46(3):227-35. DOI:10.1055/s-0035-1549992
  • Aktuelle Urologie 05/2015; 46(3):177-8. DOI:10.1055/s-0035-1555703
  • [Show abstract] [Hide abstract]
    ABSTRACT: Advanced urothelial carcinoma of the bladder is associated with a high metastatic potential. Life expectancy for metastatic patients is poor and rarely exceeds more than one year without further therapy. Neoadjuvant chemotherapy can decrease the tumour burden while reducing the risk of death. Adjuvant chemotherapy has been discussed controversially. Patients with lymph node-positive metastases seem to benefit the most from adjuvant chemotherapy. In selected patients, metastasectomy can prolong survival. In metastastic patients, the combination of gemcitabine and cisplatin has become the new standard regimen due to a lower toxicity in comparison to the combination of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC). For second-line treatment, vinflunine is the only approved therapeutic agent. © Georg Thieme Verlag KG Stuttgart · New York.
    Aktuelle Urologie 05/2015; 46(3):242-7. DOI:10.1055/s-0035-1549948
  • [Show abstract] [Hide abstract]
    ABSTRACT: Radical cystectomy (RC) with bilateral pelvic lymph node dissection constitutes the gold standard treatment for muscle-invasive and high-risk non-muscle-invasive urothelial carcinoma of the bladder refractory to instillation therapy. Although radical cystectomy is performed with curative intent, the overall 5-year survival has been reported to be as low as 62% in the current literature. Various clinico-pathological parameters determine post-RC outcome, but besides these, the role of comorbidity has gained increasing attention and can be quantified with various comorbidity scores. We here review the most recent data on comorbidity scores and performance indices, which have been assessed in patients, undergoing RC and highlight their clinical implications. © Georg Thieme Verlag KG Stuttgart · New York.
    Aktuelle Urologie 05/2015; 46(3):236-41. DOI:10.1055/s-0035-1550036
  • [Show abstract] [Hide abstract]
    ABSTRACT: Metastatic involvement of the penis is rare. Secondary lesions generally originate from pelvic tumours. Bladder and prostate are the most common primary tumours. Commonly, penile metastases occur in cases of disseminated cancer disease. We present the case of a prostatic mucinous adenocarcinoma with a solitary, PSA-negative, asymptomatic metastasis to the glans 6 years after radical prostatectomy, which was successfully treated by local excision. © Georg Thieme Verlag KG Stuttgart · New York.
    Aktuelle Urologie 03/2015; DOI:10.1055/s-0035-1547231
  • [Show abstract] [Hide abstract]
    ABSTRACT: Nowadays to ascertain medical history is not the only way of communication between the person concerned and the physician. Dealing with a complaint or a disease includes gaining information by surfing on the internet too. The internet offers blogs with the possibility to put a question anonymously. One of these blogs is part of the website "die Blase.de" of Dr. R. Pfleger Arzneimittel in Bamberg, Germany. The requests of 20 months have been evaluated. The typical user of this blog is female; thematically - side effects of a current therapy, seeking a solution for complex continence problems or a refractory therapy and capacity building measures were most frequent. The complexity of the particularised continence problems and the extensive searches for a qualified physician support the offer of an internet-based doctor's consultation in due consideration of a taboo topic such as urinary incontinence. © Georg Thieme Verlag KG Stuttgart · New York.
    Aktuelle Urologie 03/2015; 46(2):144-147. DOI:10.1055/s-0035-1545346
  • [Show abstract] [Hide abstract]
    ABSTRACT: Prostate-specific antigen (PSA) has revolutionized the management of prostate cancer (PCa) within the last 3 decades. This widely used tumour marker strongly correlates with the risk of harbouring a PCa but it lacks specificity. Therefore there is an urgent need for new biomarkers especially to detect clinically significant and aggressive PCa. Of all PSA-based markers, only the FDA-approved prostate health index phi shows improved specificity over percent free (%fPSA) and total PSA. Other serum kallikreins or sarcosine in serum or urine show more ambiguous data. In urine, the FDA-approved prostate cancer gene 3 (PCA3) has also proven its utility in the detection and management of early PCa with advantages as compared with PSA and %fPSA. However, some aspects of its correlation with aggressiveness and the low sensitivity at very high values have to be re-examined. The detection of alterations of the androgen regulated TMPRSS2 and ETS transcription factor genes in tissue of ~50% of all PCa patients was a milestone in PCa research. But only the combination of the urinary assays for TMPRSS2:ERG gene fusion and PCA3 (both use the same platform) show the expected improved accuracy for PCa detection. Comparisons of phi and PCA3, the best available PCa biomarkers so far, show an equal performance of both parameters. © Georg Thieme Verlag KG Stuttgart · New York.
    Aktuelle Urologie 03/2015; 46(2):129-143. DOI:10.1055/s-0034-1398544
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: After radical prostatectomy (RP) the pre-RP PSA value, Gleason Score, pT-stage, state of seminal vesicles and state of surgical margins are key indicators for the risk of biochemical or clinical recurrence. Depending on the tumour stage, 50-70% of the high-risk patients suffer biochemical progression. The treatment options in these circumstances are adjuvant radiotherapy (ART, for an undetectable PSA) or salvage radiotherapy (SRT, for persisting PSA or PSA re-rising above detection limits). Data from ongoing randomised trials that compare ART and SRT directly have not yet been published. Method: A search in PubMed for ART and SRT after RP for prostate cancer was undertaken to compare the results of the 2 treatment approaches. Results: 3 randomised phase-III studies have shown a nearly 20% advantage in terms of biochemical progression after ART (60-64 Gy) compared with a wait-and-see strategy. The largest effect was seen in patients with pT3 prostate cancer with positive surgical margins. According to the German S3-guidelines, SRT with at least 66 Gy can be offered to patients with a post-RP persisting PSA or a PSA re-rising above detection limits. 30-70% of these patients re-achieve an undetectable PSA. Thus, there is a second option for curative treatment. Due to the lower total dose, ART seems to be connected with fewer late complications than SRT. SRT, on the other hand, reduces the risk of potential interactions with post-RP complications and of overtreatment. There is a controversial discussion about the inclusion of the pelvic lymph nodes in the treatment volume, the additional application of anti-androgens and the total dose of both ART and SRT. Conclusions: The comparison of SRT after PSA progression with ART at a PSA below the detection limits cannot yet be judged conclusively. The indication for ART depends on the associated risk factors. However, regarding freedom from biochemical progression, it is backed up by high level evidence. If SRT is applied for biochemical progression, then it should be initiated early, i. e., at the lowest PSA possible. © Georg Thieme Verlag KG Stuttgart · New York.
    Aktuelle Urologie 01/2015; 46(1):52-58. DOI:10.1055/s-0034-1395656
  • [Show abstract] [Hide abstract]
    ABSTRACT: Therapy for metastatic castration-resistant prostate cancer (mCRPC) has become more complex due to recent medical findings. Today different options for first- and second-line treatment are available. Therefore scientific attention focuses on possible sequences and combinations. Besides, biomarkers play an important role as they can support therapeutic decisions and may enable more focused therapies. A new evaluation of biomarkers for advanced prostate cancer is necessary since the tumour biology is changing. One prognostic marker in mCRPC is PSA but this marker has to be interpreted with caution in this situation. Validated predictive markers for mCRPC are still lacking. In some studies potential predictive markers have been analysed. © Georg Thieme Verlag KG Stuttgart · New York.
    Aktuelle Urologie 01/2015; 46(1):66-70. DOI:10.1055/s-0034-1396859
  • [Show abstract] [Hide abstract]
    ABSTRACT: Prostate cancer is still the most common urological cancer of the elderly man. In some patients, a metastatic prostate cancer arises which may remain a stable disease for years with palliative antiandrogen therapy. On average, after 3-4 years, affected men develop a PSA rise and disease progression with the formation of a so-called castration-resistant disease. 5 years ago cytotoxic chemotherapy with docetaxel was the only life-prolonging treatment option in this situation. In the last 5 years, the results of randomised phase III studies have led to the approval of 5 new agents for the treatment of metastatic castration resistant prostate cancer (mCRPC). The results and approval status of the substances, Abiraterone, Enzalutamide, Cabazitaxel, Sipuleucel-T and radium-223 are described below. In addition, some aspects of sequential therapy and possible future molecular approaches are discussed. © Georg Thieme Verlag KG Stuttgart · New York.
    Aktuelle Urologie 01/2015; 46(1):59-65. DOI:10.1055/s-0034-1395655
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: In various studies it has been shown that obesity enhances the risk for a unfavorable pathological tumour stages, higher Gleason scores (GS), positive surgical margins (PSM), and certain perioperative parameters (higher blood loss, higher length of surgery, higher complication rates) after radical prostatectomy. However, for robot-assisted radical prostatectomy (RARP) there are only a few studies addressing this topic with partially conflicting results. Furthermore, none of these studies actually represents the clinical practice pattern as performed in a European centre. Material and Methods: Beside further clinical and histopathological parameters, also body mass index (BMI) of patients undergoing RARP was recorded. The following categories were registered: BMI of < 25 kg/m², ≥ 25-29.9 kg/m², and ≥ 30 kg/m² defined as normal weight, overweight, and obesity, respectively. The potential correlation between BMI on the one hand and various criteria of aggressive tumour biology and specific perioperative parameters on the other hand has been examined on univariate and multivariable analyses. Results: 22.8% (n=79), 59% (n=204), and 18.2% (n=63) of patients of the study group presented with normal weight, overweight, and obesity, respectively. Based on the results of various multivariable regression models there was no significant influence of obesity on pathological tumour stage, pN category, undifferentiated tumour growth (≥ GS7b), upgrading, or PSM rates. Furthermore, obese patients showed a significantly higher intraoperative blood loss and a higher length of surgery, which, however, did not result in a higher rate of grade 3a/b complications according to Clavien-Dindo classification after 90 days. Conclusions: In the present series of consecutive patients undergoing RARP there was no evidence for a more aggressive tumour biology or a higher complication rate in obese patients.
    Aktuelle Urologie 11/2014; 45(6). DOI:10.1055/s-0034-1394427
  • [Show abstract] [Hide abstract]
    ABSTRACT: Histologically defined subtypes of renal cell tumors (clear cell, papillary, chromophobe, oncocytoma) have to be accepted as distinct tumor entities based on specific and distinct molecular alterations and different prognosis. Immunochemistry and genetic analysis can be used for diagnosis in uncertain cases and are more and more important for individual therapy selection. Differentiation of prognosis in each subtype seems possible by using molecular signatures of primary tumors allowing individual assessment of aggressiveness and metastatic potential. Molecular markers from blood as well as from tumor tissues can predict therapy response in the future. In order to transfer these promising data into clinical practice it is mandatory to develop validation studies which have to be performed based on defined criteria similar to those for therapeutic clinical trials.
    Aktuelle Urologie 09/2014; 45(5):370-373. DOI:10.1055/s-0034-1389946
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: The aim of this study was to evaluate the current quality-of-care in newly diagnosed non-muscle invasive bladder cancer pa-tients with regard to immediate postoperative and adjuvant intravesical instillation therapy. Methods: Using a standardised questionnaire, we collected clinical and follow-up data from 250 patients with newly diagnosed urothelial carcinoma of the bladder (UCB) between February 2008 and October 2012 from urological health-care practitioners. Since diagnostic and therapeutic decisions were not influenced by a specific protocol, these findings are representative of current practice patterns. Results: 250 patients were available for analysis. Immediate postoperative instillation chemotherapy was performed in 82 (44.8%) of 183 evaluable patients. Only seldom did clinics give therapeutic advice on adjuvant therapy. Patients -received in the mean 10.5 instillations. Administration of adjuvant intravesical therapy was associated no side effects in 95%, and was completed according to protocol in 87% of the patients. Conclusion: Our descriptive study presents current findings and practice patterns in patients with newly diagnosed UCB. Rates of immediate postoperative instillation chemotherapy were lower than expected. Bladder instillation therapy was well tolerated. In most of the patients therapy was completed according to the protocol. There are still differences in urological practice patterns as compared to the relevant guidelines.
    Aktuelle Urologie 09/2014; 45(5):377-380. DOI:10.1055/s-0034-1389929
  • [Show abstract] [Hide abstract]
    ABSTRACT: Retropubic tumours without contact to bones or surrounding tissues are extremely rare with only 22 cases being reported in the literature. The majority of tumours described within these reports are osteochondromas in 17 cases, 2 cases of leiomyoma and one case of each fibroma, fibrosarcoma and nodular fasciitis. We now report the case of a 52-year-old-man with a retropubic ganglion cyst, which was resected "in toto" by laparoscopy.
    Aktuelle Urologie 08/2014; 45(5). DOI:10.1055/s-0034-1385906
  • [Show abstract] [Hide abstract]
    ABSTRACT: The scrotal leiomyoma is a rare benign tumour, deriving from the smooth muscle. This tumour entity constitutes a differential diagnosis to malignant testicular tumours. Up to now, only 8 cases have been reported in the literature. We report on a 63-year-old European patient, presenting in our clinic for further treatment with a now monstrous mass of the left testis (about 8 kg) that has been growing for about 30 years, After partial scrotalectomy and orchiectomy pathological analysis confirmed a left-sided leiomyoma of the testicular/paratestical tissue. This case shows that even rare tumours should be included in the differential diagnosis of a testicular tumour.
    Aktuelle Urologie 07/2014; 45(4):293-295. DOI:10.1055/s-0034-1385898
  • [Show abstract] [Hide abstract]
    ABSTRACT: The prognosis of advanced penile carcinomas is extremely poor. Low numbers of available studies on chemotherapy over a long time, decentralized treatment as well as rareness of disease have not improved the prognosis. This article focuses on important clinical trials and developments for chemotherapy in penile cancer. Considering the latest study data there is a strong recommendation for multimodal approaches, including lymph node dissection and perioperative treatments with cisplatin/taxane-based chemotherapy. A systematic, centralized registration and evaluation by the "Rostocker-AUO-Register" for penile cancer should improve conditions for affected patients. Furthermore, molecular targeted therapy might be a promising therapeutic option but until now only very few case reports have been published. Further prospective clinical trials are necessary to establish these agents in the therapeutic landscape of penile cancer. Decision for palliative chemotherapy in advanced penile cancer should be well considered and depends on the patient's age and general condition particularly regarding possible adverse events of chemotherapy. Notably, best supportive care might be an important alternative for some patients and should be taken in consideration.
    Aktuelle Urologie 07/2014; 45(4):286-292. DOI:10.1055/s-0034-1385897
  • [Show abstract] [Hide abstract]
    ABSTRACT: Through the last decade considerations on the role of vitamins and antioxidants in the primary prevention of genitourinary tumors have changed dramatically. In spite of all efforts, the efficacy of a specific compound has not been proven so far. In consequence, recommendations to use vitamins or other supplements for the primary prevention of urological tumors should be avoided. However, there is some evidence that moderate food consumption, reduction of dairy products and an Asian or Mediterranean diet may not only prevent prostate cancer (PCA) but also harbour additional beneficial effects on general health. Although quantification of these findings may be difficult, it becomes evident that these measures will have additional synergistic effects on cardiovascular diseases. Considering the large number of PCA patients dying not cancer-related but from concomitant diseases, primary prevention in particular of PCA should always also consider the general health of the target population. More recent studies suggest a potential effect of nutritional compounds on biochemical tumour recurrence in PCA patients after definite therapy. These observations may serve as a starting point for validation within controlled clinical trials.
    Aktuelle Urologie 07/2014; 45(4):281-285. DOI:10.1055/s-0034-1383645